Canine Vaccine Market Size
| Study Period | 2022 - 2029 |
| Market Size (2024) | USD 3.40 Billion |
| Market Size (2029) | USD 5.20 Billion |
| CAGR (2024 - 2029) | 6.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Canine Vaccine Market Analysis
The Canine Vaccine Market size is estimated at USD 3.40 billion in 2024, and is expected to reach USD 5.20 billion by 2029, growing at a CAGR of 6.20% during the forecast period (2024-2029).
The canine vaccine market is driven by rising dog adoption and increased awareness of animal diseases. Rising animal bite incidents, animal welfare campaigns, and supportive government initiatives are expected to drive growth in the canine vaccine market.
Additionally, the increase in dog adoption in recent years is driving the growth of the canine vaccine market over the forecast period. For instance, For instance, according to the 2023-2024 National Pet Owners Survey conducted by the American Pet Products Association (APPA), around 66% of United States households own a pet, which includes 65.1 million dogs in 2023. Hence, dogs are listed as the most adopted animals, and due to their vulnerability to various diseases, the demand for vaccinations to prevent these ailments in cats and dogs is projected to rise during the forecast period.
Additionally, the increase in animal shelters for street dogs and the increase in their protection are also driving the growth of the market. For instance, according to Shelter Animal Count Data, in 2023, around 3.2 million dogs were in need of care and assistance.
According to data updated by the World Health Organization in September 2023, globally, nearly USD 8.6 billion is spent on rabies each year, and 29 million people receive post-exposure prophylaxis as an emergency response to rabies exposure. According to the Federal Capital Territory (FCT), in Nigeria, more than 20,000 people are annually estimated to have rabies in Africa, with over 95% of mortalities attributed to dog bites. Therefore, increasing zoonotic diseases such as rabies are creating demand for canine vaccines. Thus boosting the market growth over the forecast period.
However, the high cost of vaccine development and regulatory concerns are expected to limit market growth during the forecast period.
Canine Vaccine Market Trends
Attenuated Live Vaccines Segment is Projected to Show Significant Growth Over the Forecast Period
Live-attenuated vaccines have become increasingly popular due to their effectiveness in providing long-lasting immunity. These vaccines use a weakened form of the virus or bacteria that causes the disease, which helps the immune system recognize and fight the pathogen without causing the actual illness.
In the context of canine vaccines, live-attenuated vaccines are also widely used. For example, the canine distemper vaccine is often a live-attenuated vaccine. This type of vaccine is particularly effective for dogs because it stimulates a strong immune response, providing robust and long-lasting protection against diseases.
The rise in demand for live-attenuated vaccines in both human and veterinary medicine can be attributed to their ability to mimic natural infection closely, leading to better immunity. Additionally, advancements in vaccine technology have made these vaccines safer and more accessible. For instance, according to an article published in the National Library of Medicine in May 2023, Mucosal Vaccination with Live-Attenuated Bordetella bronchiectasis, a Gram-negative bacterium responsible for canine infectious respiratory disease complex, protects against Challenges in Wistar Rats.
The growing use of the live attenuated vaccine for the canine vaccine market is expected to grow significantly. Bordetella bronchiseptica is an aerobic gram-negative bacterium in dogs. B. bronchiseptica is highly contagious, leading to bronchitis (kennel cough). There are very few cases of B. bronchiseptica in humans. The risk of B. bronchiseptica colonization and sporular infections is higher in patients with impaired immunity. For intranasal administration of the B. bronchiseptica vaccine, cats and dogs can receive Live Atapulated Vaccines. These live attenuated vaccines are considered to be safe, but zoonotic infections can occur under the right conditions.
Therefore, the increased use of live attenuated vaccines for most canines will likely show substantial growth in the forecasted period.
North America is Expected to Dominate the Canine Vaccine Market during the forecast period.
The companion animal health market is projected to be dominated by North America during the forecast period due to rising dog adoption, Increased awareness among canine owners about canine healthcare, and innovative product launches by the major companies, which drives the target market further. According to Shelter Animal Count Data, in 2023, around 2.2 million dogs, representing 56% of the total intake, found new homes in the United States.
As per the same source, in the United States, around 46.5 million households, roughly 50% of all homes, own a dog. Dogs ranked as the first most prevalent house pet in the country. This shows the greater adoption of pets in the country which increases the need for vaccinations to prevent diseases in pets, thereby boosting the market growth in the country.
Furthermore, according to the 2023-2024 National Pet Owners Survey conducted by the American Pet Products Association (APPA), pet expenditures in the United States increased to USD 136.8 million in 2022 compared to USD 138.6 billion in 2022. Thus, growing pet healthcare expenditures in the country may raise spending on animal health and treatment, which is likely to contribute to the veterinary vaccines market over the forecast period.
Therefore, the canine vaccine market will likely grow over the forecast period due to the above factors.
Canine Vaccine Industry Overview
The canine vaccine market is consolidated. Some companies dominate it, including Vetoquinol, Boehringer Ingelheim, Merck Animal Health, Ceva Santé Animale, and Zoetis. These global players control most of the market. However, few companies are entering it and are expected to hold a significant share soon.
Canine Vaccine Market Leaders
-
Boehringer Ingelheim International GmbH.
-
Zoetis Services LLC
-
Merck & Co., Inc
-
Vetoquinol
-
Ceva
*Disclaimer: Major Players sorted in no particular order
Canine Vaccine Market News
- October 2024: Calviri has initiated a new vaccine trial targeting early-stage hemangiosarcoma (HSA) in dogs. The investigational immunotherapy vaccine aims to activate the immune system to identify and destroy cancer cells.
- August 2024: Starting August 1, 2024, the CDC will implement new rules for bringing dogs into the United States to prevent the reintroduction of canine rabies.
Canine Vaccine Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Adoption of Dogs
4.2.2 Increased Incidence of Zoonotic Diseases
4.3 Market Restraints
4.3.1 Regulatory Concerns and the Expensive Costs of Vaccine Development
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value)
5.1 By Vaccine Type
5.1.1 Attenuated Live Vaccines
5.1.2 Inactivated Vaccines
5.1.3 Subunit Vaccines
5.1.4 DNA Vaccines
5.1.5 Recombinant Vaccines
5.2 By Adminstration Routes
5.2.1 Subcutaneous
5.2.2 Intramuscular
5.2.3 Intranasal
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Vetoquinol S.A
6.1.2 Boehringer Ingelheim
6.1.3 Ceva Santé Animale
6.1.4 Eli Lilly and Company
6.1.5 Heska Co.
6.1.6 Merck Animal Health
6.1.7 Sanofi
6.1.8 Virbac
6.1.9 Zoetis
6.1.10 Phibro Animal Health Corporation
6.1.11 Durvet Inc.
6.1.12 HIPRA
6.1.13 Brilliant Bio Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Canine Vaccine Industry Segmentation
As per the scope of the study, A canine vaccine is a biological preparation that provides active acquired immunity to specific diseases in dogs. These vaccines contain agents that resemble the disease-causing microorganisms, which are often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. When administered, they stimulate the dog’s immune system to recognize the agent as a threat, destroy it, and remember it, so the immune system can more easily recognize and destroy any of these microorganisms it encounters in the future.
The canine vaccine market is segmented by vaccine type, including attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines. The administration process includes subcutaneous, intramuscular, and intranasal, By geography includes North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.
| By Vaccine Type | |
| Attenuated Live Vaccines | |
| Inactivated Vaccines | |
| Subunit Vaccines | |
| DNA Vaccines | |
| Recombinant Vaccines |
| By Adminstration Routes | |
| Subcutaneous | |
| Intramuscular | |
| Intranasal |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Canine Vaccine Market Research FAQs
How big is the Canine Vaccine Market?
The Canine Vaccine Market size is expected to reach USD 3.40 billion in 2024 and grow at a CAGR of 6.20% to reach USD 5.20 billion by 2029.
What is the current Canine Vaccine Market size?
In 2024, the Canine Vaccine Market size is expected to reach USD 3.40 billion.
Who are the key players in Canine Vaccine Market?
Boehringer Ingelheim International GmbH., Zoetis Services LLC, Merck & Co., Inc, Vetoquinol and Ceva are the major companies operating in the Canine Vaccine Market.
Which is the fastest growing region in Canine Vaccine Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Canine Vaccine Market?
In 2024, the North America accounts for the largest market share in Canine Vaccine Market.
What years does this Canine Vaccine Market cover, and what was the market size in 2023?
In 2023, the Canine Vaccine Market size was estimated at USD 3.19 billion. The report covers the Canine Vaccine Market historical market size for years: 2022 and 2023. The report also forecasts the Canine Vaccine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Canine Vaccine Industry Report
Statistics for the 2024 Canine Vaccine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Canine Vaccine analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
